Frazier Life Sciences Public Fund, L.P. 13D and 13G filings for KalVista Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-07 2:34 pm Purchase |
2024-11-05 | 13D | KalVista Pharmaceuticals, Inc. KALV |
Frazier Life Sciences Public Fund, L.P. | 4,887,867 10.000% |
1,200,000 (+32.54%) |
Filing |
| 2024-02-22 1:22 pm Purchase |
2024-02-20 | 13D | KalVista Pharmaceuticals, Inc. KALV |
Frazier Life Sciences Public Fund, L.P. | 3,687,867 8.900% |
105,573 (+2.95%) |
Filing |
| 2023-12-14 1:33 pm Purchase |
2023-12-12 | 13D | KalVista Pharmaceuticals, Inc. KALV |
Frazier Life Sciences Public Fund, L.P. | 3,582,294 10.400% |
343,435 (+10.60%) |
Filing |
| 2022-12-30 2:15 pm Purchase |
2022-12-28 | 13D | KalVista Pharmaceuticals, Inc. KALV |
Frazier Life Sciences Public Fund, L.P. | 3,238,859 9.500% |
1,666,667 (+106.01%) |
Filing |
| 2022-01-31 5:00 pm Purchase |
2022-01-26 | 13D | KalVista Pharmaceuticals, Inc. KALV |
Frazier Life Sciences Public Fund, L.P. | 1,572,192 6.400% |
303,463 (+23.92%) |
Filing |
| 2021-12-30 4:33 pm Purchase |
2021-12-21 | 13D | KalVista Pharmaceuticals, Inc. KALV |
Frazier Life Sciences Public Fund, L.P. | 1,268,729 5.200% |
1,268,729 (New Position) |
Filing |